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WAP four-disulfide core domain protein
2 promotes metastasis of human ovarian
cancer by regulation of metastasis-
associated genes
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Abstract
Background: WAP four-disulfide core domain protein 2 (WFDC2) shows a tumor-restricted upregulated pattern of
expression in ovarian cancer.
Methods: In this study, we evaluated the role of WFCD2 in tumor mobility, invasion and metastasis of ovarian
cancer in clinical tissue and in ovarian cancer cells, both in vitro and in vivo.
Results: Our results revealed WFCD2 was overexpressed in ovarian tissues, and the expression level of WFCD2 was
associated with metastasis and lymph node metastasis. Higher expression of WFCD2 was also observed in aggressive
HO8910-PM cells than in HO8910 cells, and WFCD2 knockdown halted cell migration, invasion, tumorigenicity and
metastasis in ovarian cancer cells, both in vitro and in vivo. Knockdown of WFDC2 induced the down-regulation of
ICAM-1, CD44, and MMP2.
Conclusion: In summary, our work demonstrates that WFCD2 promotes metastasis in ovarian cancer. These findings
suggest that WFCD2 plays a critical role in promoting metastasis and may constitute a potential therapeutic target of
ovarian cancer.
Keywords: WFCD2, Ovarian cancer, Metastasis, Cell migration and invasion;
Background
Among women, ovarian cancer is one of the most
common gynecological cancers worldwide. With the
highest mortality rate of all gynecologic cancers,
ovarian cancer is very problematic to treat. Even after
optimal treatment, more than half of patients suffer
recurrence and eventually die [1].
Tumor progression is generally associated with
extensive tissue remodeling to provide a proper envi-
ronment for tumor growth, angiogenesis, invasion,
and eventual metastasis of cancer cells. It is known
that proteases are key agents in tumor progression,
and that naturally expressed protease inhibitors have
the ability to counteract tumor progression and me-
tastasis [2–4]. However, expression of serine protease
inhibitors (SPIs) in tumors is often associated with
poor prognosis in cancer patients. Moreover, there is
growing evidence that SPIs may even promote cancer
cell malignancy which, if confirmed, could make them
useful biomarkers of malignancy [5].
A recent study has identified WFCD2 as a new
member of the group of serine protease inhibitors
belonging to the WAP family. While prior research
indicated a direct linkage between WFCD2 expression
and cell proliferation [6, 7], its physiological and
pathological mechanisms in tumorigenesis and metas-
tasis have not been clearly elucidated.
Human WFCD2 gene located on chromosome
20q12–13.1 locus, which encode a serial of proteins
with a WAP-type four disulphide core (WFDC)
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domain [8, 9]. More and more evidence suggests that
overexpression of WAP-type proteins closely related
to tumor metastasis, especial SLPI and P13 (encode
antileukoproteinase 1 and elafin respectively). Both
SLPI and P13 are co-expressed with WFCD2 and have
been identified as a promoter in cancer development
in various carcinomas [10, 11]. Expression of SLPI is
positively correlated with increased expression of the
cell cycle progression factor Cyclin D1 [12, 13], and
its causal role in the promotion of malignant behavior
has also been demonstrated in lung carcinoma cells
stably transfected with human SLPI-expression
constructs [14]. Elafin (P13) also has a role in coun-
teracting environmental proteolytic conditions and
repair-processes that are commonly associated with
the inflammatory response, cancer progression, and
invasion of various tumor cells [3, 15].
In view of the above information, the WAP
proteins, had been considered as being associated
with high-risk, metastatic, or aggressive cancer origi-
nating from various organs [9, 16]. We speculated
that WFCD2 might also play some role in tumor
progression in ovarian cancer.
Our previous study indicated that knockdown of
WFCD2 induced the up-regulation of Fasl and down-
regulation of Cyclin D1, as well as activating Caspase
3 and Ki67 [6]. These results indicate that WFCD2
plays very important roles in tumor formation and
proliferation. In the presented study, we analyze the
expression of WFCD2 in ovarian cancer cell line
HO8910 and aggressively malignant line HO8910-PM.
A cell model of WFCD2 gene down-regulation was
constructed and used to analyze the function of
WFCD2 in tumor metastasis and tumorigenesis in
vitro and in vivo.
Methods
Ethic statement
Ovarian tumors were obtained from a cohort of patients
treated at Nanfang Hospital, affiliated with Southern
medical University, China, between 2011 and 2014. All
research involving human ovarian cancer tissues have
been approved by Nanfang hospital ethics committee
and written consent was obtained from all participants.
The 6- to 8-week-old female BALB/c–nu mice used in
these experiments were provided by the experimental
animal center of the Southern Medical University
(Guangzhou, China). All mouse studies were approved
by the Animal Ethics Committee of the Southern
Medical University (Permit Number 20060015). All work
was undertaken and that it conforms to the provisions
of the declaration of Helsinki (as revised in Fortaleza,
Brazil, October 2013).
Patients and tissue samples
The median age of the patients was 50.8 years. All
patients were diagnosed by pathological analyses based
on the International Union Against Cancer (UICC)
tumor node metastasis (TNM) stage system. 100 tissue
samples (Table 1) from normal ovarian, primary tumors
and matched adjacent non-neoplastic ovarian tissues
were collected and prepared for Anti-WFCD2 polyclonal
antibody (Abcam, Cambridge, MA, USA) was used as
primary antibody. The staining intensity (0, no staining;
1, weak staining; 2,moderate staining; and 3, intense
staining) and the proportion of stained cells (0, no
staining; 1, <10% staining; 2, between 11 and 33%
staining; 3, between 34 and 66% staining; and 4, >67%
staining) were semiquantitatively determined. The inten-
sity and the percentage of positive cell scores were
multiplied (0–12) and classified into three groups: weak
(0–4), moderate (5–8) and strong (9–12). All slides were
scored by two observers blinded to the pathology and
the clinical features.
Table 1 Distribution by tumor characteristics for ovarian cancer
patients
Variable No. patients (%)
n %
Total
Age(years)
≤ 50 38 38
> 50 62 62
FIGO stage
Stage I 26 28.57
Stage II 21 23.08
Stage III 31 34.07
Stage IV 12 13.19
Grade(Epithelial, n = 91)
G1 29 31.87
G2 46 50.55
G3 16 17.58
Histological type
Serous cystadenocarcinoma 46 50.55
Mucinous cystadenocarcinoma 22 24.18
Endometrioid tumor 14 15.38
Clear cell cacinoma 9 9.89
Transcoelomic Metastasis
No 65 71.42
Yes 26 28.57
Lymph node metastasis
No 74 81.31
Yes 17 18.69
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Cell lines and reagents
Human ovarian cancer cell lines SKOV3, HO8910 and
HO8910-PM were purchased from the cell bank of the
Chinese Academy of Sciences (Shanghai, China). The
cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) media supplemented with 10% fetal
calf serum (FBS) in an atmosphere of 5% CO2 at 37 °C.
Restriction enzymes from TAKARA (TaKaRa Bio, Inc.,
Shiga, Japan); Transwell system from CostarCorning
(Corning, NY, USA).; Puromycin and Trizol reagent
from Invitrogen (Life Technologies, Carlsbad, CA, USA);
cell culture media (antibiotic, serum and glutamine)
from GIBCO (Life Technologies, Carlsbad, CA, USA).
All other molecular reagents and solvents were
purchased from SIGMA Corp (St. Louis, MO, USA).
Gene knockdown
WFCD2 knockdown was conducted in low-passage (<20)
ovarian cancer cells. The shRNA oligo sequences were de-
signed to against the human WFCD2 gene (Gene Bank
Accession No. NM_0006103.3). The shRNA sequence
against WFCD2(5′-GCTCTCTGCCCAATGATAAGG-3′)
and a invalid RNAi sequence(5′-GTTCTCCGAACGT
GTCACGT-3′) were chemically synthesized and con-
structed into the lentiviral by Shanghai Genepharma
Co.Ltd. The WFCD2-specific shRNA lentivirus paticals
was collected and transfected into the HO8910 and
SKOV3 cell lines. For stable knockdown of WFCD2, the
transfected HO8910 and SKOV3 cell lines, named
HO8910–209 and SKOV3–209 respectively, were selected
by Puromycin. Puromycin-resistant colonies were picked
and expanded separately.
RNA extraction and real-time RT-PCR
Total RNA was isolated with Trizol regents and reverse
transcription was performed using the PrimeScript 1st
Strand cDNA Synthesis Kit, according to the manufac-
turer’s instructions, cDNA samples (0.1 μg) were assayed
in duplicate using the ABI Prism 7500 detection system
(Life Technologies, Carlsbad, CA, USA). Using the SYBR
Green PCR Master Mix (TaKaRa) following protocols.
The relative quantization number was then calculated by
subtracting the average CT from the corresponding
average CT for β-actin.
Tumour migration assay
Transwell polycarbonate plates with 6.5 mm diameter
tissue culture inserts containing a membrane with 8 μm
pores were used for migration assay. Low passage (<20)
cells were cultured in the medium without serum to
synchronize most of them at G1/G0 and then suspended
in serum-free DMEM and seeded (5 × 104 cells/well)
into each insert. The condition medium with 10% FBS
collected after 24 h culture was added to each outer well.
The plates were then assembled and incubated for 8 h at
37 °C, 5%CO2. After a 8 h incubation, the plates were
rinsed once in PBS, fixed in 70% alcohol for 10 min, and
rinsed with 0.5% crystal violet. Cells adhering to the top
surface of the tissue culture inserts were removed with a
cotton tip applicator, while cells adhering to the bottom
surface of the inserts were rinsed with 1% Triton-X 100
in PBS for 20 min. The membranes of the tissue culture
inserts were viewed under amicroscope (10× magnifica-
tion) and the number of cells in 4 random fields was
determined.
Tumour invasion assay
For invasion assays, 5 × 104 cells (cell passage <10) were
cultured in the medium without serum to synchronize
most of them at G1/G0 and then plated in DMEM/1%
FBS in a cell invasion chamber (Transwell Cell invasion
assay kit, Corning) in a 24-well plate, which contained
an 8 μm pore size polycarbonate membrane covered
with a thin layer of collagen matrix. Invasive cells mi-
grated through a membrane according to the gradient of
FBS to the lower chamber, which contained DMEM/15%
FBS. The invasive cells were stained with crystal violet,
and the number of cells in 4 random 10× magnification
fields was determined.
In vivo tumor formation and peritoneal dissemination
For the generation of intraperitoneal tumors, HO8910-
NA cells and HO8910–209 cells were injected intraperito-
neally (i.p.) into mice (n = 10). Each mouse received one
injection of 3 × 106cells. Animals were monitored 3 times
weekly for tumor formation. All injection-treated mice
were fed for 10 weeks after injection. At the end of
10 weeks, all the mice were sacrificed and the abdominal
region examined for tumor formation. Each tumor burden
in the peritoneal cavity was weighed and collected and
paraffin-preserved according to the usual protocols.
Western blot
Total protein was extracted by sonication in radio-
immunoprecipitation assay (RIPA) buffer(50 mM
Tris–HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, 0.5%
Nonidet P-40, 5 mM dithiothreitol, 10 mM NaF,
protease inhibitor cocktail). 100 μg denaturedprotein
was separated on an SDS-polyacrylamide gel and
transferred to Hybond membrane (Amersham,
Germany), which was then blocked overnight in 5%
skimmed milk inTris-bufferedsaline with Tween 20
(TTBS, 10 mM Tris–HCl, 150 mM NaCl, 0.1% Tween
20). For immunoblotting, the membrane was incu-
bated for 15 min with antibodies. The membrane was
rinsed with TBST and incubated with anti-mouse,
anti-rabbit or anti-goat IgG conjugated to horseradish
peroxidase (DAKO, USA, 1:1000) for 15 min. All the
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incubations were performed in a microwave oven to
allow intermittent irradiation. Bands were visualized
with LAS4010 (GE Healthcare Life Science, USA) by
ECL-Plus detection reagents (Santa Cruz, USA).
Densitometric quantification of protein bands was
performed with GAPDH as an internal control using
Image J (NIH, USA).
Immunohistochemistry
Immunohistochemistry was done using a single-staining
procedure. Anti-WFCD2, anti-Ecadherin,anti-Vimentin
monoclonal antibody (Cell Signaling Technology), anti-
CD44,anti-MMP2,anti-MMP9,and anti-ICAM-1 rabbit
polyclonal antibody (Santa Cruz Biotechnology), were
applied to the slides at a dilution of 1:1,00 ~ 1:150 in
blocking buffer overnight at 4 °C. The slides were then
washed and stained by the avidin-biotin method. The
slides were lightly counter stained with hematoxylin.
Tumor cells were considered positive for the antigen if
there was brown color staining. The intensity was scored
as negative (0), weak (1), medium (2), and strong (3),and
the proportion of staining was scored as 1 (≤10%), 2
(11–50%), 3 (51–75%), and 4 (>75%). An overall expres-
sion score was calculated by multiplying the scores for
intensity and proportion, ranging from 0 to 12. For
ICAM-1, at least 500 tumor cell for each xenograft sam-
ple (n = 5) were randomly selected and counted. The
number of positive cell was counted and the positive
index was calculated as follows: ICAM-1 index = (number
of stained cells/total cell number) × 100%.
Statistical analysis
All experiments were performed at least in triplicate. All
data are reported as the mean ± standard deviation.
Using Excel 2007 (Microsoft Corporation, Redmond,
WA, USA). Microsoft Office Excel 2007 (Microsoft
Corporation, Redmond, WA, USA) and the statistical
software SPSS13.0 (SPSS Inc., Chicago, IL, USA) were
used in data processing and analyzing the significance
with the one-way ANOVA,t-Test,or the log rank test
(for Kaplan-Meier plots). Results with P < 0.05 were
considered statistically significant.
Results
Increased expression of WFCD2 correlated with the
progression and peritoneal metastasis of human
ovarian cancer
To examine the potential clinical relevance of WFCD2
to ovarian cancer progression, the human ovarian cancer
tissues were derived from patients with progressive
ovarian disease to investigate WFCD2 expression and its
association with different clinicopathological parameters.
Undetectable to very low WFCD2 staining were ob-
served in normal ovarian tissue, whereas ovarian
carcinomas showed higher WFCD2 immunoreactivity in
most cases (Fig. 1a). The WFCD2 staining score of
carcinomas is significantly higher than that of non-
neoplastic ovarian tissues (all FIGO stage), which re-
vealed a correlation between WFCD2 expression levels
and ovarian cancer progression (Fig. 1b), while no sig-
nificence had been observed between high-grade carcin-
omas and low-grade carcinomas. Next, the correlation
between WFCD2 expression and key clinical parameters
in human ovarian cancer were assessed. There were no
significant correlations between high WFCD2 expression
and patient age or histological subtypes. While consist-
ent with the results in migration and invasion assay in
vitro, peritoneal transcoelomic dissemination was posi-
tively associated with the expression of WFCD2. The
expresoion of WFCD2 was higher in primary tumors
with peritoneal metastasis and lymph node metastasis
sample (Fig. 1c-d). The Kaplan-Meir survival graphs in
Fig. 1e display the association of WFDC2 expression
with ovarian cancer survival. As shown in Fig. 1e, the
degree of expression of WFDC2 were significantly
associated with longer survival in EC (log rank
p = 0.0117).Taken together, these data strongly indicate
that enhanced WFCD2 may play a role in the progres-
sion of the primary ovarian cancer cell to peritoneal
metastasis.
Expression of WFCD2 mRNA and protein in HO8910
and HO8910-PM cells
HO8910 is a poorly differentiated human ovarian serous
adenocarcinoma cell line and removed from a patient with
serous ovarian Cystadeno carcinoma as well as ascites.
The HO8910PM cell line was derived from HO8910
grown as xenografts in nude mice and was considered to
possess more invasive and metastatic potential than
HO8910 cell lines [17]. Real-time RT-PCR showed that
WFCD2 mRNA was expressed more strongly in
HO8910PM cells, at levels 8 times higher than that ob-
served in the HO8910 cells (p < 0.005) (Fig. 2a). Secreted
WFCD2 protein was detected only at very low levels in
the medium containing HO8910 cells, but was amplified
three folds in the HO8910-PM cells by comparison
(p < 0.005) (Fig. 2b). These results, with significantly dif-
ferent levels of WFCD2 expression between HO8910 and
HO8910PM, indicate that WFCD2 might be involved in
cell invasion and the metastasis of ovarian cancer cells.
WFCD2 knockdown reduces cell migration, invasion
WFCD2 knockdown was conducted in HO8910 and
SKOV3 ovarian cancer cells (see Additional file 1:
Figure S1). Before we did the cell migration and inva-
sion assay, we had considered that the knockdown of
WFDC2 cause slower growth and reduced cycling D
level and may cause confused in the result. So before
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we seed the cells into the culture insert, we starved
the cell for 12 h by culturing in the medium without
serum. So all the cells would be synchronize most of
them at G1/G0 to reduce the confounding effects of
reduced cell proliferation in the knockdown cells. The
transwell system was used for migration and invasion
assay. The migration assay showed that the number
of WFCD2 knockdown cells passing through the
membrane was much lower than the control cells
(Fig. 3a, b). In the invasion assay, a polycarbonate
membrane over which a thin layer of extracellular
matrix (ECM) was applied served as an in vitro base-
ment membrane. Since only invasive cells are capable
of migrating through the ECM layer, we observed that
the number of cells passing through the ECM layer
was much lower in the WFCD2 knockdown group
than the control. This result indicated that cells of
control group readily passed through the membrane,
the WFCD2-knockdown cells were in large part
unable to invade the matrix, (Fig. 3a, b), indicating
that overexpression of WFCD2 in ovarian cancer
might heighten the potential for tumour metastasis.
WFCD2 knockdown reduces and peritoneal implantation
potential of ovarian cancer cells
Tumor growth and peritoneal dissemination was also
evaluated in vivo. We utilized the intraperitoneal xeno-
graft mouse model with WFCD2 knockdown and the
control cells. 10 weeks after tumor inoculation, mice
were sacrificed and we measured the peritoneal disse-
mination of the mice. Figure 4a shows the effects of
WFCD2 knockdown on the peritoneal dissemination of
ovarian cancer cells. In the negtive control group, many
peritoneally disseminated tumors (marked with arrows)
Fig. 1 Over-expression of WFDC2 was correlated with stage and peritoneal metastasis in ovarian cancer. a Representative images of WFDC2
expression in normal ovarian tissue and primary ovarian cancer tissues (FIGO I, II, III, and IV) are shown (200× magnificaiton); bWFDC2 is
significantly increased in specimens from ovarian cancer tissue compare with the normal ovarian tissue(*P < 0.05;); c WFDC2 scores are
significantly higher in primaray tumors with metastasis than in non-metastasis specimens(*P < 0.05;). d WFDC2 scores are significantly higher in
primaray tumors with lymph mode metastasis than in non-lymph mode metastasis specimens(*P < 0.05;).(E) Kaplan-Meier survival curves for 72
ovarian cancer patients, stratified based on individual WFDC2 expression(*P < 0.05;)
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Fig. 2 Expression of WFDC2 in HO8910 cell line and high metastatic potential HO8910PM cells. a Normalized WFDC2 genes mRNA levels in the
HO8910 and HO8910-PM. The relative quantities of WFDC2 protein were determined by densitometry and normalized by using β-actin. *P < 0.05
compared to HO8910; b Western blot analysis of expression of WFDC2 and GAPDH. Normalized WFDC2 protein levels in ovarian cancer cell lines
HO8910 and HO8910PM. The relative quantities of WFDC2 protein were determined by densitometry and normalized by using GAPDH. *P < 0.05
HO8910-PM compared to HO8910
Fig. 3 WFCD2 knockdown reduces cell migration, invasion. a Assessment of cell migration and invasion of WFDC2 knockdown lines and control. b
Quantification of the migration and invasion is expressed as the number of invasive cells per HPF. Bottom, representative micrographs of the transwell
migration and invasion assay (10× magnification) * P < 0.05 ** <0.01 WFDC2 knockdown (sh-WFDC2) compared to negative control (sh-NA)
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were observed, whereas in the WFDC2 knockdown mice
peritoneal dissemination was clearly suppressed. Peritoneal
disseminated tumors had been observed in 8 of 10 mice in
the negtive control group group, while only 3 mice in
WFDC2 knockdown group were found to have tumor me-
tastases. Peritoneal and mesenteric nodules were observed
in the liver (6/10), intestines (8/10) and abdomen (3/10) in
the mice of the negtive control group. However, in mice of
the WFDC2 knockdown group, peritoneal and mesenteric
nodules were absent from abdominal organs, though some
were found in the intestine (3/10). These data indicate that,
compared with the control group, the growth and metasta-
sis of tumors were markedly inhibited by WFCD2 gene
knockdown (Fig. 4b). The sizes and number of peritoneal
and mesenteric nodules at 10 weeks after the transplant-
ation ofWFDC2 knockdown cells were significantly smaller
and fewer than that of the control group (Fig. 4b).
The pro-malignant activity of WFCD2 is mediated by its
effect on CD44,MMP2 and ICAM-1 expression
Since reduced exogenous secretion of WFCD2 in WFCD2
gene knockdown mice resulted in a significant suppres-
sion of tumorigenesis and metastasis. We suspect that
WFCD2 promotes the peritoneal implantation of ovarian
cancer cells. To explore the mechanisms of tumor inhib-
ition by WFCD2 knockdown in vivo, the animals were
sacrificed and the expression of the genes related to
tumorigenesis and metastasis were detected by immuno-
histochemistry (CD44,ICAM-1,VCAM-1,MMP2,MMP9).
In our study, CD44 and MMP2 staining showed that
membrane localization of this protein was reduced when
WFCD2 was depleted (Fig. 5a, d, f ). We also found that
the number of positive cells in the ICAM-1 staining was
lower in the WFCD2 knockdown cells compared to the
control (Fig. 5a, c). The IHC results had been comfirmed
by qRT-PCR (Additional file 1: Figure S2). These results
confirm the relationship between the WFCD2 and cell
tumorigenesis and metastasis of cancer cells.
Discussion
Various regulators are involved in the processes of ma-
lignancy and metastasis. Recent evidence suggests that
proteins of the WAP family play an important role in
tumor progression, malignancy, and metastasis [9, 18].
WFCD2 is one of themembers of theWAP family and pre-
vious research has shown that the blood concentration of
WFCD2 is higher in patients with ovarian cancer than in
women with either healthy ovaries or benign ovarian tumors
[8, 19, 20]. Thus we hoped to identify the role of WFCD2 in
the malignancy and metastasis of ovarian cancer. In the
present study, we analyzed the expression ofWFCD2 in ovar-
ian cancer cell lines HO8910 and HO8910PM. The latter is
derived from HO8910 and is considered to have more po-
tency in invasion and metastasis than its parent HO8910 cell
lines.We observed a higher expression ofWFCD2 in both the
RNA and protein level in HO8910PM cells than that in
HO8910 cells. These data indicate that WFCD2 may be a
tumor-specific gene involved in the malignancy and metasta-
sis of ovarian cancer. A comparable correlation between
Fig. 4 WFDC2 Promoted the metastasis and of peritoneal implantation of ovarian cancer cell. a WFDC2 knockdown suppressed growth of HO8910
ovarian cancer cells in the peritoneum compared with the negative control on week 10 after transplanting. b Effect of WFDC2 knockdown on peritoneal
dissemination was assessed by counting the number of nodules and evaluating tumor size in the mesentery and peritoneal wall compared with controls.
Ten mice were used in each group. Each value represents mean ± s.e. * P < 0.05, WFDC2 knockdown (sh-WFDC2) compared to negative control (sh-NA)
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WFCD2 expression and the malignant behavior of ovarian
carcinoma cells has also been established.
Our results shows that the high expression of
WFCD2 is ovarian cancer tissues of all FIGO stages,
and positively correlated to lymph node metastasis
(p < 0.05) and implanted metastasis (p < 0.05), which
indicates that high expression of WFCD2 may relate
to the progression of ovarian cancer. Hence, WFCD2
may be a potential biomarker of clinical staging and
may possibly be a biomarker for prognosis assess-
ment. However, the application value of clinical
examination still needs further evaluation.
After knockdown of WFCD2 expression, the inva-
sion and migration rate was significantly lower in the
WFCD2 cells compared to the blank control both in
HO8910 and SKOV3 cells. The decreased malignancy
of these ovarian cancer cells was confirmed to be
associated with the lower levels of WFCD2. This
suggests that WFCD2 accelerates the migration and
invasion of ovarian cancer cells, as expected.
Unlike most solid tumors, ovarian cancer spreads
mainly via implantation within the peritoneal cavity, and
hematogenous metastasis is seldom observed [18, 21–23].
The invasive and migratory capacity of ovarian cancer
cells plays a key role in the metastasis process. To
determine if the changes observed in vitro as a result
of WFCD2 knockdown are reproducible in vivo, we
established an ovarian cancer xenograft model. This
in vivo study using WFCD2 gene-knockdown ovarian
cancer cell HO8910–209 showed that WFCD2 knock-
down suppressed both ovarian tumor growth and
peritoneal dissemination. The type of destination or-
gans, the number of metastases, and the amount of
nodules in HO8910–209 groups were significantly
Fig. 5 The expression of ICAM-1,MMP2 and CD44 on WFDC2 and WFDC2 knockdown cells. a WFDC2,ICAM-1 and CD44 immunohistochemistry in
WFDC2 knockdown and negative control xenografts; Xenograft tumor sections (HO8910) were stained with either anti-WFDC2 antibody,anti-CD44
antibody,anti-MMP2 or anti-ICAM-1 antibody. b, c, d, e.Normalized WFDC2,ICAM-1,MMP2and CD44 protein levels in WFDC2 knockdown and
negtive control xenografts. *P < 0.05 WFDC2 knockdown compared to negative control; f Summary of WFDC2-mediated molecular effects on
ovarian cancer metastasis
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lower than in the control groups. These results are
consistent with the results in vitro, and confirm that
WFCD2 knockdown inhibits cell migration and inva-
sion, thereby inhibiting the malignancy and metastasis
of ovarian cancer.
Many factors can affect the tumour metastasis. Our pre-
vious study indicated that knockdown of WFCD2 induced
cell apoptosis and depressed cell proliferation [6]. In this
study, several biochemical markers used to characterize
metastases had been evaluated by immunohistochemical
methods to further elucidate the role of WFCD2 in
tumorigenicity in vivo. In these biochemical markers, such
as ICAM-1, VCAM-1, CD44, MMP2, MMP9, we ob-
served that the expression of CD44, MMP2 and ICAM-1
was significantly reduced in WFCD2 knockout tumor
cells, which might explain WFCD2 knockdown reduced
the mobility of tumor cells both in vitro and in vivo (Re-
sults are schematically summarized in Fig. 5f). ICAM-1 is
an important cell-adhesion molecule directly linked to
ovarian tumor growth, metastasis and chemo-resistance
[24]. CD44 is a receptor for hyaluronic acid,up-regulation
of CD44 represents a crucial event in the development of
metastasis, recurrence, and drug resistance to current
treatments in ovarian cancer. MMP-2 (along with MMP-
9) is capable of degrading type IV collagen, the most
abundant component of the basement membrane. The
interaction of MMP2 and CD44 is an important factor in
selectively regulating the tumor microenvironment to
promote tumor cell metastasis and is considered to be an
inducer of EMT [22, 25, 26]. To be interesting, Hokins etl
had also reported that paracrine SLPI secretion upregu-
lated MMP2 and MMP9 transcription and secretion in
some cancer cells [24, 25]. All this suggests a role for
WFCD2 in rebuilding the tumor microenvironment by
regulating the expression of MMP2 and CD44. As both
CD44 and MMP2 are inducer of epithelial-mesenchymal-
transition (EMT),which strengthens our confidence that
WFCD2 might participate in tumor metastasis and disease
processes by regulating the progression of EMT in ovarian
cancer cells. However, the role of WFCD2 as a regulator
in EMT is still required further evaluation.
Conclusion
In summary, we show that WFCD2, which is up-
regulated in ovarian cancer, can now for the first time be
considered a regulator of tumor metastasis. These
results provide fresh impetus for further exploration into
metastasis in ovarian cancer. We propose WFCD2 as a
potential therapeutic target and prognostic marker for
ovarian cancer and believe that uncovering these
processes will provide key information that extends our
understanding of the occurrence and development of
ovarian cancer and its treatment.
Additional file
Additional file 1: Figure S1. Expression of WFDC2 in WFDC2
knockdown Clonal Lines. (A) Western blot analysis of expression of WFDC2
and GAPDH in SKOV3 cells. Normalized WFDC2 protein levels in the
shRNA-transfectant, mock-transfectant NA and control. The relative
quantities of WFDC2 protein were determined by densitometry and
normalized by using GAPDH. *P < 0.05 compared to mock-transfectant
sh-NA; #P < 0.05 compared to SKOV3. (B) Western blot analysis of expression
of WFDC2 and GAPDH in HO8910 cells. Normalized WFDC2 protein levels in
the shRNA-transfectant, mock-transfectant sh-NA. The relative quantities of
WFDC2 protein were determined by densitometry and normalized by using
GAPDH. *P < 0.05 compared to sh-NA; Figure S2. The genes related to
metastasis were modified by WFDC2 knockdown. Normalized metastasis
related genes mRNA levels in the WFDC2 knockdown and negative control
cells. The relative quantities of WFDC2,ICAM-1,CD44 and MMP2 mRNA were
determined by densitometry and normalized by using β-actin. *P < 0.05
compared to sh-NA. (DOC 470 kb)
Abbreviations
CD44: Cluster of Differentiation 44; EMT: Epithelial mesenchymal transition;
ICAM-1: Intercellular adhesion molecule; IHC: Immunohistochemistry;
MMP2: Matrix metalloproteinase-2; MMP9: Matrix metalloproteinase-9;
NC: Negative control; qPCR: Quantitative real-time PCR; VCAM-1: Vascular cell
adhesion molecule 1; WFDC2: WAP four-disulfide core domain 2
Acknowledgments
This work was supported by grants from the National High Technology Research
and Development Program of China (863 Program) (No. 2012AA020205). This
work was also supported by Guangzhou major collaborative innovation research
projects (201508020052).
Availability of data and material
Not applicable.
Authors’ contributions
Conceived and designed the experiments: YC LTC SHW YSW JLL ML.
Performed the experiments: YC SHW LTC. Analyzed the data: YC YSW JLL ML.
Contributed reagents/materials/analysis tools: YC LTC SHW. Wrote the paper:
YC YSW JLL ML. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
All authors declare that no conflict of interest exits in the submission of
this manuscript, and that the manuscript has been approved by all
authors for publication.
Ethics approval and consent to participate
All mouse studies were approved by the Animal Ethics Committee of the
Southern Medical University (Permit Number 20060015). All work was
undertaken and that it conforms to the provisions of the declaration of
Helsinki (as revised in Fortaleza, Brazil, October 2013).
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1School of Laboratory Medicine and Biotechnology, Southern Medical
University, Guangzhou 510515, China. 2State Key Laboratory of Organ Failure,
Guangdong Provincial Key Laboratory of Tropical Disease Research, Southern
Medical University, Guangzhou 510515, China. 3Obstetrics and Gynecology
Center, Nanfang Hospital, Guangzhou 510515, China. 4Institute of Antibody
Engineering, Southern Medical University, 1023 Shatainan Road, Guangzhou
510515, China. 5Department of Oncology, Molecular Oncology Laboratories,
Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3
9DS, UK.
Chen et al. Journal of Ovarian Research  (2017) 10:40 Page 9 of 10
Received: 29 November 2016 Accepted: 24 April 2017
References
1. Hertlein L, Stieber P, Kirschenhofer A, Krocker K, Nagel D, Lenhard M, et al.
Human epididymis protein 4 (HE4) in benign and malignant diseases. Clin
Chem Lab Med. 2012;50(12):2181–8.
2. Cheng JD, Dunbrack RL Jr, Valianou M, Rogatko A, Alpaugh RK, Weiner LM.
Promotion of tumor growth by murine fibroblast activation protein, a serine
protease, in an animal model. Cancer Res. 2002;62(16):4767–72.
3. Wei H, Hellstrom KE, Hellstrom I. Elafin selectively regulates the sensitivity of
ovarian cancer cells to genotoxic drug-induced apoptosis. Gynecol Oncol.
2012;125(3):727–33.
4. Westin U, Nystrom M, Ljungcrantz I, Eriksson B, Ohlsson K. The presence of
elafin, SLPI, IL1-RA and STNFalpha RI in head and neck squamous cell
carcinomas and their relation to the degree of tumour differentiation.
Mediat Inflamm. 2002;11(1):7–12.
5. Wang R-F, Zhang L-H, Shan L-H, Sun W-G, Chai C-C, Wu H-M, et al. Effects
of the fibroblast activation protein on the invasion and migration of gastric
cancer. Exp Mol Pathol. 2013;95(3):350–6.
6. Chen Y, Mu X, Wang S, Zhao L, Wu Y, Li J, et al. WAP four-disulfide core
domain protein 2 mediates the proliferation of human ovarian cancer cells
through the regulation of growth- and apoptosis-associated genes. Oncol
Rep. 2013;29(1):288–96.
7. Moore RG, Hill EK, Horan T, Yano N, Kim K, MacLaughlan S, et al. HE4
(WFDC2) gene overexpression promotes ovarian tumor growth. Sci
Reports. 2014;4:3574.
8. Angioli R, Plotti F, Capriglione S, Montera R, Damiani P, Ricciardi R, et al. The
role of novel biomarker HE4 in endometrial cancer: a case control
prospective study. Tumour Biol. 2013;34(1):571–6.
9. Bouchard D, Morisset D, Bourbonnais Y, Tremblay GM. Proteins with
whey-acidic-protein motifs and cancer. Lancet Oncol. 2006;7(2):167–74.
10. Henriksen PA, Hitt M, Xing Z, Wang J, Haslett C, Riemersma RA, et al.
Adenoviral gene delivery of elafin and secretory leukocyte protease
inhibitor attenuates NF-kappa B-dependent inflammatory responses of
human endothelial cells and macrophages to atherogenic stimuli. J
Immunol (Baltimore, Md : 1950). 2004;172(7):4535–44.
11. Scott A, Weldon S, Taggart CC. SLPI and elafin: multifunctional antiproteases
of the WFDC family. Biochem Soc Trans. 2011;39(5):1437–40.
12. Devoogdt N, Hassanzadeh Ghassabeh G, Zhang J, Brys L, De Baetselier P,
Revets H. Secretory leukocyte protease inhibitor promotes the tumorigenic
and metastatic potential of cancer cells. Proc Natl Acad Sci U S A. 2003;
100(10):5778–82. doi:10.1073/pnas.1037154100.
13. Zhang D, Simmen RCM, Michel FJ, Zhao G, Vale-Cruz D, Simmen FA.
Secretory leukocyte protease inhibitor mediates proliferation of human
endometrial epithelial cells by positive and negative regulation of
growth-associated genes. J Biol Chem. 2002;277(33):29999–30009.
14. Nukiwa T, Suzuki T, Fukuhara T, Kikuchi T. Secretory leukocyte peptidase
inhibitor and lung cancer. Cancer Sci. 2008;99(5):849–55.
15. Caruso JA, Hunt KK, Keyomarsi K. The neutrophil elastase inhibitor elafin
triggers rb-mediated growth arrest and caspase-dependent apoptosis in
breast cancer. Cancer Res. 2010;70(18):7125–36. doi:10.1158/0008-5472.
CAN-10-1547.
16. Jalkanen J, Kotimaki M, Huhtaniemi I, Poutanen M. Novel epididymal
protease inhibitors with Kazal or WAP family domain. Biochem Biophys Res
Commun. 2006;349(1):245–54.
17. Zhou LYX, Wang Y, Zhang YT, Geng YP, Si LS, Wang YL. Identification of
metastasis-associated proteins of ovarian cancer by proteomics. Zhonghua
Bing Li Xue Za Zhi. 2007;36(12):814–8.
18. Noel A, Albert V, Bajou K, Bisson C, Devy L, Frankenne F, et al. New
functions of stromal proteases and their inhibitors in tumor progression.
Surg Oncol Clin N Am. 2001;10(2):417–32. x-xi.
19. Manolov V, Marinov B, Vasilev V, Andreeva A. HE4–a new tumor marker for
ovarian cancer. Akusherstvo i ginekologiia. 2011;50(Suppl 2):11–5.
20. Zou SL, Chang XH, Ye X, Cheng HY, Cheng YX, Tang ZJ, et al. Effect of
human epididymis protein 4 gene silencing on the malignant phenotype in
ovarian cancer. Chin Med J. 2011;124(19):3133–40.
21. Naora HMD. Ovarian cancer metastasis: integrating insights from disparate
model organisms. Nat Rev Cancer. 2005;5(5):355–66.
22. Shao MHCL, Shen CY, Satpathy M, Chelladurai B, Bigsby RM, Nakshatri H,
Matei D. Epithelial-to-Mesenchymal transition and ovarian tumor progression
induced by tissue transglutaminase. Cancer Res. 2009;69(24):9192–201.
23. Tan DSPAR, Kaye SB. Mechanisms of transcoelomic metastasis in ovarian
cancer. Lancet Oncol. 2006;7(11):925–34.
24. Hoskins E, Rodriguez-Canales J, Hewitt SM, Elmasri W, Han J, Han S, et al.
Paracrine SLPI secretion upregulates MMP-9 transcription and secretion in
ovarian cancer cells. Gynecol Oncol. 2011;122(3):656–62.
25. Sakata K, Shigemasa K, Nagai N, Ohama K. Expression of matrix
metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1,
TIMP-2) in common epithelial tumors of the ovary. Int J Oncol. 2000;17(4):673–81.
26. Choi B-D, Jeong S-J, Wang G, Park J-J, Lim D-S, Kim B-H, et al. Secretory
leukocyte protease inhibitor is associated with MMP-2 and MMP-9 to
promote migration and invasion in SNU638 gastric cancer cells. Int J Mol
Med. 2011;28(4):527–34.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Chen et al. Journal of Ovarian Research  (2017) 10:40 Page 10 of 10
